MedTrace Logo

Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects

NCT01652339 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-03-26

No results posted yet for this study

Summary

To assess the pharmacokinetic characteristics of Lodivixx tab.5/160mg in healthy male subjects

* PK parameter evaluation
* Safety profile evaluation

Conditions

  • Healthy Male Subjects

Interventions

DRUG

Exforge tab. 10/160mg

DRUG

Lodivixx tab. 5/160mg

Sponsors & Collaborators

  • Hanlim Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jae Gook Shin, MD · Inje University

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-08-31
Completion
2012-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01652339 on ClinicalTrials.gov